Abstract:
The invention relates to the field of carbohydrate chemistry. Provided is a process for the regioselective oxidation of a single secondary hydroxy function of a carbohydrate substrate comprising two or more secondary hydroxy functions, comprising contacting the carbohydrate substrate in a solvent in the presence of a transition metal catalyst complex with an oxidizing agent to yield a mono-oxidized carbohydrate.
Abstract:
La présente invention concerne l'utilisation de composés comprenant un cycle cyclopentane, substitué en positions (1) et (3) par des groupements aminés, primaires, secondaires ou tertiaires, identiques ou différents, éventuellement protégés par un groupement protecteur, lesdits groupements aminés étant en configuration cis, pour la préparation d'un médicament destiné au traitement des maladies microbiennes, telle que les infections bactériennes, les viroses ou les mycoses.
Abstract:
Novel aminoglycosides, represented by Formulae (I), (Ia), (III) and (IIIa), as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
Abstract:
The invention relates to the field of chemical derivatization. In particular, it relates to modified aminoglycosides, such as antibiotics, and methods for producing them. Provided is a method for the regioselective diazotation of a desoxy-streptamine- substituted aminoglycoside, comprising contacting the aminoglycoside with imidazole- -sulfonyl azide hydrochloride under neutral p H conditions to allow for the conversion of the single amine group at the 3-C position of the desoxy-streptamine ring into an azide group. Also provided are novel antibiotic compounds.
Abstract:
The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin.
Abstract:
Compounds of structure (I): having antibacterial activity are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q 1 , Q 2 , Q 3 , R 8 and R 9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Abstract:
Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
Abstract:
This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof: wherein R1 to R4. R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.
Abstract translation:本发明涉及式1A化合物或其药学上可接受的盐:其中R1至R4。 R 7,R 9至R 12和Y如本文所定义。 本发明还涉及包含所述化合物或其药学上可接受的盐的药物组合物; 以及其用于降低或逆转细菌对至少一种氨基糖苷类抗生素的抗性的方法。